BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Bio Reports

China Plus One: Slogan, Strategy, or Capacity APAC Does Not Have?

THE RESHUFFLE · ANALYSIS On a Monday in June 2026, one line in the United States Federal Register did what two year...

July 15, 2026 | Analysis

The Technology Is Ready. Are APAC’s Regulators?

In a process-development suite in Singapore, or Hyderabad, or Songdo, a perfusion bioreactor can now run for weeks, its output feeding straight into a conn...

July 15, 2026 | Regulatory

Q32 Bio Reports Positive Phase 2a Results for Bempikibart in Severe Alopecia Areata, Plans Pivotal Programme

-- Clinically meaningful efficacy data on the primary endpoint was observed with a mean percent reduction in SALT score from baseline o...

July 15, 2026 | News

Can APAC Biomanufacturing Decarbonise Without Pricing Itself Out?

Scope 3 clauses, single-use plastic, water and energy intensity: the “green premium” has become the defining question for the CDMOs that built ...

July 14, 2026 | Analysis

The Algorithm on the GMP Floor: AI Promises a Smarter Plant. Regulators Demand the Audit Trail.

A control room that thinks it knows what happens next Walk the mezzanine above a modern biologics suite in Singapore, Songdo or Hyderabad and the change i...

July 13, 2026 | Analysis

APAC's Peptide-Capacity Gamble

For most of pharmaceutical history, the hard part was finding a molecule that worked. The GLP-1 class inverted that logic. The science arrived first &mdash...

July 09, 2026 | Analysis

Singapore Updates Wegovy Label to Include Higher-Dose Semaglutide Data Showing Up to 25% Weight Loss

Up to one in three participants on semaglutide 7.2 mg achieved at least 25% weight loss over 72 weeks Mean weight loss with semaglutide 7.2 mg reached 2...

July 09, 2026 | News

After the Rush: APAC's mRNA and Vaccine Capacity Hangover

In June 2022, South Korea had something it had wanted for two years: a COVID-19 vaccine of its own. SKYCovione, developed by SK bioscience with the U...

July 08, 2026 | Analysis

The Biosimilar Race: Factory to the World — or Stuck in the Copycat Economy?

In Songdo and Bengaluru, the numbers finally look like the ones the region was promised a decade ago. Celltrion closed 2025 with revenue above ₩4 trillio...

July 07, 2026 | Analysis

The Vein-to-Vein Problem: Can APAC's Cold Chain Carry Advanced Therapies?

The requirement: a chain that cannot break Key figures −150°C or colder — the temperature floor for most cell and gene therapies; som...

July 06, 2026 | Analysis

Vectors, Plasmids and the CGT Trap: APAC's Cell and Gene Therapy Ambitions Face an Upstream Bottleneck

THE GATE The choke point nobody puts on the slide Somewhere in the region this quarter, a cell-and-gene developer has everything the pitch deck promised....

July 03, 2026 | Analysis

Can APAC Build Radioligand Therapy Before the Atoms Decay?

Every dose of radioligand therapy is a countdown. The moment a batch of lutetium-177 leaves the reactor, it begins to fade — roughly half its therape...

July 02, 2026 | Analysis

The Great Biopharma Reset: 50 Developments That Changed Everything in H1 2026

For three years the biotechnology industry waited for a turn. The first half of 2026 delivered one — and then several more in quick succession. In si...

June 30, 2026 | Analysis

Beyond the Obvious Giant: Where APAC's Clinical Trials Go Next

For most of the last decade, the strategic case for running Asia-Pacific clinical trials could be summarised in a single word: China. A vast, treatment-n...

June 29, 2026 | Analysis

Stay Connected